Breast cancer, Vitali (Daiichi Sankyo): “Synergy with Astrazeneca to accelerate drug development and distribution”

“In 2019 we started a collaboration with Astrazeneca both to accelerate the development of the innovative technology of trastuzumab deruxtecan and to accelerate and spread this drug in all countries worldwide”. These are the words of Mauro Vitali, head of Oncology of Daiichi Sankyo Italia, on the sidelines of the press conference 'Breast cancer: the new frontiers of treatment', organized in Milan by AstraZeneca and Daiichi Sankyo. At the center of the conference, dedicated to the presentation of new perspectives for the treatment of metastatic breast cancer with low levels of expression of the Her2 receptor, is the monoclonal antibody drug conjugate trastuzumab deruxtecan, whose reimbursement has been approved by Aifa also for this type of patients.